Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Down-staging nab-paclitaxel plus gemcitabine for locally advanced pancreatic cancer (CAP-005)
jRCTs031180318Phase 2Completed
- Sponsor
- Kojinkai
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel, gemcitabine and tegafur in pancreatic cancer (PC), sponsored by Kojinkai. Primary endpoint: R0 resection rate. Started May 2016; status: completed.
02
Drugs
paclitaxelgemcitabinetegafur
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCTs031180318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180318.